Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
130.89
-3.64 (-2.71%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.
Via
Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
September 05, 2024
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Via
Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
September 05, 2024
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges.
Via
Benzinga
Novo Nordisk Unusual Options Activity
September 05, 2024
Via
Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
September 05, 2024
Lilly just lowered the price of Zepbound.
Via
The Motley Fool
Looking At Novo Nordisk's Recent Unusual Options Activity
August 27, 2024
Via
Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
September 05, 2024
Could this beaten-down stock turn things around in the near future?
Via
The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
September 05, 2024
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering.
Via
Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
September 04, 2024
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla.
Via
Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
September 04, 2024
BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, the company plans to list on Nasdaq under the symbol BIOA. Their lead drug,...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
September 04, 2024
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is...
Via
Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
September 03, 2024
Via
Benzinga
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
September 02, 2024
Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound.
Via
Benzinga
Exposures
Product Safety
Market Thoughts This Labor Day Weekend
September 01, 2024
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will...
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
August 31, 2024
Ozempic may offer unexpected anti-aging benefits, potentially improving health and reducing mortality rates, according to new research.
Via
Benzinga
3 No-Brainer Stocks to Buy in September
August 31, 2024
There's at least one key common denominator here: tremendous growth prospects.
Via
The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
August 31, 2024
This competitive showdown just saw one of the players hit a couple of bumps.
Via
The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
August 30, 2024
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
August 30, 2024
Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials published by The Lancet. While not approved for heart failure outcomes in the US,...
Via
Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
August 30, 2024
The addressable market for the treatments could potentially contract significantly.
Via
The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
August 29, 2024
Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.
Via
The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
August 28, 2024
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Via
Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
August 27, 2024
The single-dose vials will also increase supply, the drug giant says.
Via
Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
August 27, 2024
Shareholders don't have too much to fear -- yet.
Via
The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
August 26, 2024
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Via
MarketBeat
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
August 26, 2024
Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senator Sanders and experts remain critical as a Senate hearing looms next...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.